Rare cardiac rhythm disease

Rare cardiac rhythm disease (Orphanet code 218436) is a broad classification category encompassing a group of uncommon disorders that affect the electrical conduction system of the heart, leading to abnormal heart rhythms (arrhythmias). These conditions disrupt the normal generation or propagation of electrical impulses that coordinate heartbeats, potentially resulting in rhythms that are too fast (tachycardia), too slow (bradycardia), or irregular. The primary body system affected is the cardiovascular system, though secondary effects on the brain, kidneys, and other organs can occur due to compromised blood flow. Key clinical features across this group of diseases may include palpitations, syncope (fainting), dizziness, chest discomfort, exercise intolerance, and in severe cases, sudden cardiac arrest or sudden cardiac death. Some patients may be asymptomatic and are only identified through routine electrocardiogram (ECG) screening or family screening after a relative is diagnosed. The severity and presentation vary widely depending on the specific underlying condition, which may include entities such as Brugada syndrome, long QT syndrome, short QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), progressive cardiac conduction defect, and other inherited or acquired arrhythmia syndromes. The treatment landscape for rare cardiac rhythm diseases includes pharmacological approaches (such as beta-blockers, sodium channel blockers, or antiarrhythmic drugs), lifestyle modifications (avoidance of specific triggers), and device-based therapies including implantable cardioverter-defibrillators (ICDs) and pacemakers. Catheter ablation may be appropriate for certain arrhythmia subtypes. Genetic testing and family screening play an increasingly important role in diagnosis and risk stratification. Management is typically individualized based on the specific diagnosis, genetic findings, and clinical risk profile.

Common questions about Rare cardiac rhythm disease